Zacks Investment Research
06 Nov 2025, 18:01 UTC · 45w ago
Verdict
Source says Upgrade to Buy. We score PALI +0.80 across two claims.
Score confirms the headline.
Upgrade to Buy
Rating stated in the headline
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Palisade Bio, Inc. (PALI) has been upgraded to a Zacks Rank #2 (Buy).
So whatA rating upgrade based on improving earnings estimates typically attracts buying pressure and increases near-term stock price probability.
More positive than 77% of claims this week
The upgrade for Palisade Bio is driven by an upward trend in consensus earnings estimates from sell-side analysts.
So whatPositive revisions to EPS estimates are strong indicators of improving business fundamentals and institutional valuation adjustments.
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Which stocks this story touches
More positive than 86% of ticker scores this week
The company received a Zacks Rank #2 (Buy) upgrade based on an upward trend in earnings estimates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−3.6%
Price is moving against the score
$1.62 vs $1.68 close before publication (Nov 5) · not market-adjusted
PALI chart →
